Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma

This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory non-Hodgkin's lymphoma or in relapse.

Inclusion Criteria: * Age greater than or equal to 18 years old * Patients with histologically proven, refractory or relapsed, non-Hodgkin's lymphoma as indicated for CAR T-cell therapy * ECOG score 0 to 2 * Affiliated patient or beneficiary of a social security scheme * Patient having signed prior informed consent. Exclusion Criteria: * Be under 18 years old, * Contraindication to performing 18FDG PET-CT examinations: severe claustrophobia, unbalanced diabetes during PET-CT examinations (young capillary blood sugar ≥ 11 mmol), * Any participation in other biomedical studies relating to drugs, medical devices or imaging techniques is prohibited, with the exception of so-called non-health product biomedical studies. * Hypersensitivity to the active substance or to any of the excipients in the composition of CAR T-cells preparations * Pregnant or breastfeeding women